Is West Pharmaceutical Services (WST) Pricing Justified After Mixed Returns And Rich P/E Multiple

• If you are wondering whether West Pharmaceutical Services is priced fairly or carrying a premium, the recent share performance gives an important starting clue before looking at the numbers behind it.
• The stock last closed at US$248.12, with returns of 3.2% over 7 days, 1.1% over 30 days, a 10.2% decline year to date, and a 10.1% gain over 1 year. This combination paints a mixed picture of recent sentiment.
• Recent coverage on West Pharmaceutical Services has focused on its role in pharmaceutical packaging and delivery systems and how that positioning fits within healthcare demand. This gives context to the share price moves you are seeing. Sector wide attention on medical suppliers and contract manufacturers has also kept investor interest on business quality, balance sheet strength, and long term demand visibility.
• Despite this, the company currently scores only 1 out of 6 on our valuation checks, so the next step is to compare different valuation methods. It is then useful to look at an even more complete way to think about value that ties the numbers back to the underlying story.

West Pharmaceutical Services scores just 1/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: West Pharmaceutical Services Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes the cash West Pharmaceutical Services is expected to generate in the future and discounts those projections back to what they are worth in today’s dollars.

For West Pharmaceutical Services, the latest twelve month Free Cash Flow is about $401.5 million. Analysts provide Free Cash Flow estimates out to 2027, with Simply Wall St extending the projections further. By 2035, the extrapolated Free Cash Flow figure used in this model is $411.8 million, all in $ terms. These annual cash flows are discounted using a 2 Stage Free Cash Flow to Equity approach, which separately considers an initial projection period and a later, steadier phase.

Putting those discounted cash flows together gives an estimated intrinsic value of US$102.02 per share, compared with the recent share price of US$248.12. That difference indicates the stock is assessed to be 143.2% overvalued by this particular DCF model.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests West Pharmaceutical Services may be overvalued by 143.2%. Discover 61 high quality undervalued stocks or create your own screener to find better value opportunities.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for West Pharmaceutical Services.

Approach 2: West Pharmaceutical Services Price vs Earnings

For a profitable company like West Pharmaceutical Services, the P/E ratio is a useful way to think about how much you are paying for each dollar of earnings. Higher expected growth and lower perceived risk usually justify a higher P/E, while slower growth or higher risk tend to support a lower, more conservative P/E.

West Pharmaceutical Services is currently trading on a P/E of 36.20x. That sits above the Life Sciences industry average P/E of 30.75x and also above the peer group average of 29.69x, so the market is attaching a relatively richer earnings multiple to the stock right now.

Simply Wall St’s Fair Ratio for West Pharmaceutical Services is 21.82x. This is a proprietary estimate of what a more suitable P/E could be, given factors such as the company’s earnings growth profile, profit margins, industry, market cap and specific risks. Because it blends these company specific inputs, the Fair Ratio can be more tailored than a simple comparison against broad industry or peer averages.

Comparing the current P/E of 36.20x with the Fair Ratio of 21.82x, the shares screen as expensive on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your West Pharmaceutical Services Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives step in as your way of attaching a clear story to the numbers by linking what you believe about West Pharmaceutical Services and its industry to a set of revenue, earnings and margin forecasts. These then flow through to a fair value that you can compare with the current price on Simply Wall St’s Community page, where Narratives are updated automatically when news or earnings arrive. Different investors can set very different views on the same stock. For example, one Narrative might lean toward the higher US$350 analyst target with stronger assumptions around GLP 1 and high value product demand, while another might sit closer to the lower US$260 target with more cautious expectations around contracts, tariffs and restructuring risk. This gives you a simple, visual way to see how your own view translates into a fair value that can help you decide whether the current price looks attractive or stretched.

Do you think there's more to the story for West Pharmaceutical Services? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com